Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation reports developments in synthetic biology built around its silicon-based DNA synthesis platform. Company updates cover synthetic DNA tools and services for diagnostics, therapeutics, industrial, agriculture and research markets, including oligos, genes, proteins, libraries, characterization data, antibody discovery solutions and NGS workflow tools.
Recurring announcements include fiscal results, business updates, product launches such as expanded clonal gene capabilities and library preparation kits, antibody discovery licensing, investor presentations and Nasdaq inducement equity awards for new employees.
AcornMed Biotechnology has announced a partnership with Twist Bioscience to integrate Twist's next generation sequencing (NGS) target enrichment and library preparation panels into AcornMed's cancer precision medicine tests. This collaboration aims to enhance genetic analysis for better treatment strategies. Dr. Feng Lou, CTO of AcornMed, emphasized the importance of Twist's quality DNA synthesis in improving diagnostic accuracy. The partnership is expected to positively influence patient treatment and healthcare costs in China.
Twist Bioscience (NASDAQ: TWST) has partnered with Stanford University's Innovative Medicines Accelerator to provide access to its antibody discovery services and its innovative 'Library of Libraries.' This collaboration will enable Stanford researchers to utilize Twist’s advanced synthetic antibody libraries for various therapeutic targets. Twist will receive technology access fees and share in revenue from outlicensed antibodies. The first project aims to discover novel antibodies targeting a neuroscience application. The partnership showcases Twist's commitment to advancing biologics discovery through collaboration.
Twist Bioscience (TWST) has been awarded the Great Place to Work® Certification™, an accolade based on employee feedback regarding workplace culture and experience. This certification signifies Twist's commitment to fostering a positive work environment, even during challenges like the global pandemic. CEO Emily M. Leproust highlighted the importance of employees in driving growth and success. Twist offers competitive compensation, employee development, and robust family-friendly policies. The company specializes in synthetic DNA technology, impacting multiple sectors including healthcare and agriculture.
Twist Bioscience Corporation (NASDAQ: TWST) has entered into a partnership with Kyowa Kirin Pharmaceutical Research, Inc. to discover novel antibodies targeting an undisclosed G protein-coupled receptor (GPCR). This collaboration utilizes Twist's unique 'Library of Libraries' for biologics discovery, enabling rapid antibody development. The partnership aims to enhance the efficiency and success rate of antibody therapeutics, leveraging Twist's scalable DNA manufacturing capabilities. An upfront payment was received, with Kyowa Kirin holding an option for development and commercial rights.
Twist Bioscience Corporation and Biotia have received Emergency Use Authorization (EUA) from the FDA for their SARS-CoV-2 Next-Generation Sequencing (NGS) Assay. This in vitro diagnostic test is designed to detect SARS-CoV-2 RNA with high sensitivity and analyze the entire viral RNA sequence, allowing for the identification of genetic variants. This assay is significant amid rising concerns over new viral mutations. The test enables batch processing of samples, enhancing public health responses against COVID-19. It is expected to be available for purchase soon.
Twist Bioscience Corporation (Nasdaq: TWST) announced positive preclinical data for GLP-1R antibodies from its proprietary GPCR libraries, showing effective blood glucose control. The data, published in mAbs, highlight 13 high-affinity GLP-1R antibodies that could have multiple clinical uses, including treatment for Type-2 diabetes. Notably, the antibody TB59-2 demonstrated a two-day half-life, indicating potential for once-weekly administration. CEO Emily M. Leproust emphasized collaboration with various partners to optimize antibody discovery.
Twist Bioscience Corporation (Nasdaq: TWST) has announced the shipment of new synthetic RNA reference controls for SARS-CoV-2 variants B.1.351 and P.1, as well as controls for the B.1.1.7 variant in a stabilized format. These products aim to enhance global surveillance efforts amid increasing vaccination rates. The company continues to provide essential tools to identify and monitor COVID-19 mutations, demonstrating commitment to public health. Twist's synthetic controls, based on specific SARS-CoV-2 variants, are designed to cover the full viral genome and are verified for accuracy.
Summary not available.
Twist Bioscience Corporation (NASDAQ: TWST) has partnered with Watchmaker Genomics to enhance research capabilities in high throughput sequencing applications. Their collaboration aims to facilitate innovations in oncology, inherited disease detection, and liquid biopsy assays. The first product will integrate Watchmaker's high-fidelity amplification technology into Twist's library preparation kits. Both companies focus on delivering exceptional products, optimizing workflows, and improving genomic studies quality through joint development initiatives.
Twist Bioscience Corporation (NASDAQ: TWST) has announced its participation in the virtual 2021 Advances in Genome Biology and Technology (AGBT) meeting scheduled for March 1-3, 2021. Key events include a workshop featuring customer presentations from Regeneron Genetics Center and HelioHealth, along with a poster presentation on Artificial Barcoded Libraries (ABLs) aimed at enhancing NGS sequencing. Twist's innovative DNA synthesis platform positions it at the forefront of synthetic biology, serving industries like healthcare and agriculture.